MedTrace Logo

Phase 1 Study of OSI-930 in Cancer Patients

NCT00513851 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-09-27

No results posted yet for this study

Summary

Open label, phase 1, dose escalation

Conditions

Interventions

DRUG

OSI-930

Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity

DRUG

OSI-930

Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity

Sponsors & Collaborators

  • OSI Pharmaceuticals

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2009-07-31
Completion
2009-09-30

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00513851 on ClinicalTrials.gov